NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage
biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced
that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the 2018 BIO CEO & Investor
Conference on February 12th, 2018 at 10:00 AM Eastern Time. The conference will be held at the New York Marriott Marquis
in New York, NY.
A live webcast and archive of the event can be viewed on the Company's website at www.axsome.com.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders for which there are limited treatment options. Axsome’s product candidate
portfolio includes four clinical-stage candidates, AXS-02, AXS-05, AXS-06, and AXS-07. AXS-05 is currently in a Phase 3 trial in
treatment resistant depression (TRD) and a Phase 2/3 trial in agitation in patients with Alzheimer’s disease (AD). AXS-05 is also
being developed for smoking cessation. AXS-02 is currently in a Phase 3 trial in knee osteoarthritis (OA) associated with bone
marrow lesions (BMLs) with an additional Phase 3 trial planned in chronic low back pain (CLBP) associated with Modic changes (MCs).
AXS-07 is being developed for the acute treatment of migraine. AXS-06 is being developed for the treatment of osteoarthritis and
rheumatoid arthritis and for the reduction of the risk of NSAID-associated gastric ulcers. AXS-02, AXS-05, AXS-06, and AXS-07 are
investigational drug products not approved by the FDA. For more information, please visit the company website at www.axsome.com. The company may occasionally disseminate material, nonpublic information on the
company website.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of
such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the
success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation and completion of the trials, futility analyses and receipt of interim
results, which are not necessarily indicative of the final results of our ongoing clinical trials; our ability to fund additional
clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S.
Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates;
the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the
Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the
success of the Company’s license agreements; the acceptance by the market of the Company’s product candidates, if approved; and
other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors
discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such
statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no
obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.
Axsome Contact:
Mark Jacobson
Senior Vice President, Operations
Axsome Therapeutics, Inc.
25 Broadway, 9th Floor
New York, NY 10004
Tel: 212-332-3243
Email: mjacobson@axsome.com
www.axsome.com
